Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial.

Context: There is no established pharmacological treatment for the core symptoms of chronic fatigue syndrome (CFS). Galantamine hydrobromide, an acetyl cholesterone inhibitor, has pharmacological properties that might benefit patients with CFS.

Objective: To compare the efficacy and tolerability of galantamine hydrobromide in patients with CFS.

A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.

Objective: To compare the long-term efficacy and safety of galantamine 24 mg/day and donepezil 10 mg/day in patients with Alzheimer's disease.

Patients And Study Design: This was a rater-blinded, randomised, parallel-group multicentre study (18 outpatient clinics) in the UK. 182 patients (69 male, 113 female) with Alzheimer's disease were randomised to galantamine (n = 94) or donepezil (n = 88) for 52 weeks.